|
June, 2008. MDP scientists were awarded an NIH SBIR Phase I grant to develop new diagnostic assays for gammopathies (e.g., multiple myeloma, amyloidosis, Waldenstrom’s macroglobulinemia).
February, 2008. MDP agrees to transfer its Immunohistochemistry Analyte Controls technology to a large commercial partner, who will bring it to the marketplace. MDP scientists developed the technology with funding by the National Cancer Institute, and published ten journal articles regarding it. Two U.S. patents cover this technology, and other patent applications are pending.
January-February, 2008. MDP scientists publish a new discovery platform for identifying disease-related proteins (Molecular & Cellular Proteomics, February 2008) and the first proof-of-principle clinical application, to multiple myeloma (Blood, January 1, 2008).
May, 2007. MDP scientists were awarded an NIH Phase I SBIR grant to develop a blood test for detecting cancer cells shed from solid tumors, isolated out of a small blood sample.
January, 2006. Medical Discovery Partners LLC scientists publish in two back-to-back papers (American Journal of Clinical Pathology) a new explanation as to why antigen retrieval works. Antigen retrieval is a process used in all pathology laboratories for diagnosis of biopsy specimens.
February, 2005. Medical Discovery Partners LLC scientists are awarded U.S. Patent 6,855,490, “Method for Attaching Biological Molecules to a Glass Surface”. This new U.S. patent claims a chemical linking technology used to develop and manufacture Analyte Controls for cancer testing.
July, 2004. Medical Discovery Partners LLC was awarded an SBIR Phase II grant from the National Cancer Institute. This award funds the development and clinical testing of Her-2 Analyte Controls, for more accurate and reproducible Her-2 testing. Her-2 testing is used to help decide whether to offer Herceptin® for treatment.
June, 2004. Medical Discovery Partners LLC was awarded an SBIR Phase I and II Fast-Track grant from the National Cancer Institute. This award funds the development and clinical testing of MDP’s Analyte Controls and Calibrators technology for breast cancer testing of estrogen and progesterone receptor testing. |
